HOME
>
看護学
>
臨床/成人/老人
> 生活習慣病ナーシング　8　糖尿病とメタボリックシンドローム1

生活習慣病ナーシング　8　糖尿病とメタボリックシンドローム1

出版社：	メヂカルフレンド社
著者：	近藤達也(監修) 梶尾裕(編)
発行日：	2009-07-24
分野：	看護学 > 臨床/成人/老人
ISBN：	9784839214487
電子書籍版：	2009-07-24 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

3,520 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

3,520 円(税込)

購入する

商品紹介

わが国の医療対策の最重要課題である生活習慣病をもつ患者の看護に役立つことを念頭に置いたシリーズ企画。安全・安楽な看護、根拠をもった看護の実践ができるように情報を整理。予防に対する知識から最新の治療・看護に関する知見まで、臨床の今を反映した内容。施設内医療から在宅医療の支援まで、セルフケアに必要な知識・技術に関する情報を整理。

目次

生活習慣病ナーシング　8　糖尿病とメタボリックシンドローム1　

―目次―

第１章糖尿病とメタボリックシンドローム
第２章肥満と肥満症
第３章インスリン抵抗性の概念と発生機序
第４章メタボリックシンドロームの概念と病態
第５章メタボリックシンドロームの内科的管理
第６章メタボリックシンドロームの予防・改善のための保健指導
第７章肥満・メタボリックシンドロームに関する特殊な病態

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章糖尿病とメタボリックシンドローム

P.10 掲載の参考文献

1) 小坂樹徳:インスリン非依存糖尿病(NIDDM)の病因・発症機序;概論, 日本臨床, 55(増刊):305-313, 1997.

2) Consoli A, Nurjhan N, Capani F, Gerich J:Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM, Diabetes, 38:550-557, 1989.

3) DeFronzo RA:The triumvirate:β-cell, muscle, liver. A collusion responsible for NIDDM, Diabetes, 37:667-687, 1988.

4) Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Nagai R, Kimura S, Kahn BB, Kadowaki T:A diponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated proteinkinase, Nature Med, 8:1288-1295, 2002.

5) Sone H, Yoshimura Y, Ito H, Ohashi Y, Yamada N; Japan Diabetes Complications Study Group:Energy intake and obesity in Japanese patientswith type 2 diabetes, Lancet, 363:248-249, 2004.

6) Katakura M, Naka M, Kondo T, Nishii N, Komatsu M, Sato Y, Yamauchi K, Hiramatsu K, Ikeda M, Aizawa T, Hashizume K:Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects:Naganostudy, Diabetes Care, 26:638644, 2003.

7) Katakura M, Komatsu M, Sato Y, Hashizume K, Aizawa T:Primacy of beta-cell dysfunction in the development of hyperglycemia:a study in the Japanesegeneral population, Metabolism, 53:949-953, 2004.

8) Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Matsuura T, Suzuki H, Kurose T, Yamada Y, Seino Y:Insulin secretion and insulinsensitivity at different stages of glucose tolerance:across-sectional study of Japanese type 2 diabetes, Metabolism, 53:831-835, 2004.

9) Kosaka K, Noda M, Kuzuya T:Prevention of type 2 diabetes by lifestyleintervention:a Japanese trial in IGT males, Diabetes Res Clin Pract in press.

10) 葛谷英嗣:生活習慣と2型糖尿病<門脇孝, 春日雅人, 清野進, 渥美義仁編, 矢崎義雄監:分子糖尿病学の進歩;基礎から臨床まで>, 金原出版, 2002, p 190-196.

11) 石田均, 清野裕:インスリン分泌機構とNIDDMにおける異常<小坂樹徳, 赤沼安夫編:糖尿病学>, 診断と治療社, 1996, p.33-48.

12) Niskanen L, Turpeinen A, Penttila I, Uusitupa MI Hyperglycemia andcompositional lipoprotein abnormalities as predictors of cardiovascularmortality in type 2 diabetes:a 15 year follow-up from the time of diagnosis, Diabetes Care, 21:1861-1869, 1998.

1 肥満と肥満症

P.64 掲載の参考文献

2) 日本肥満学会肥満症診療の手びき編集委員会編:肥満症;診断・治療・指導の手びき, 医歯薬出版, 1993.

3) Obesity; Preventing and managing the global epidemic, Report of a WHO consultation on obesity, Genova. 3, Global prevalence and secular trends inobesity, 1997.

4) Yoshiike, N., et al.:Descriptive epidemiology of body mass index in Japanese adult; a representative sample from the National Nutrition Survey 1990-1994. Int J Obes, 22:684, 1998.

5) 吉池信男, 他:Body Mass Indexに基づく肥満の程度と糖尿病, 高血圧. 高脂血症の危険因子との関連;多施設共同研究による疫学的検討, 肥満研究, 6 (1):4-17, 2000.

6) 松澤祐次, 他:新しい肥満の判定と肥満症の診断基準, 肥満研究, 6 (1):18-28, 2000.

7) WHO Western Pacific Regional Office, 10TF, IASO:The Asia-Pacific perspective; Redefining obesity and its treatment, In Health Communications Australia Sydney, 2000.

8) Chang, C. J., et al.:Low body mass index but high percent body fat in Taiwanese subjects; Implications of obesity cutoff, Int J Obes, 27:253-259, 2003.

9) Kissebah, A. H., et al. Relation of body fat distribution to metaboliccomplication of obesity , J Clin Endocrinol Metab, 54:254-260, 1982.

10) Nakamura, T., et al.:Contribution of visceral fat accumulation to thedevelopment of coronary artery disease in non-obese men, Atherosclerosis, 107:239-246, 1994.

11) Alberti, K. G. M. M., et al.:Metabolic syndrome; a new world-wide definition, A Consensus Statement from the International Diabetes Federation, Diabet Med, 23:469-480, 2006.

12) Hara, K., et al.:A proposal for the cutoff point of waist circumference for thediagnosis of metabolic syndrome in thc Japanese population, Diabetes Care, 29:1123-1124, 2006.

13) Miyawaki, T., et al.:Metabolic syndrome in Japanese diagnosed withvisceral fat measurement by computed tomography, Proc. Japan. Acad. 81:471-479, 2005.

14) Fujioka, S., et al.:Contribution of intra-abdominal fat accumulation to theimpairment of glucose and lipid metabolism in human obesity, Metabolism 36 54-59 1987.

15) メタボリックシンドローム診断基准検討委員会:メタポリックシンドロームの定義と診断基準日本内科学雑誌, 94:794-809, 2005

16) Nakamura, T., et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees, a case-control study, Jpn Circ J, 65, 11-17 2001.

17) Takeuchi, H., et al. Metabolic syndrome and cardlac disease in Japanese men; applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men, the Tanno and Sobetsu Study, Hypertens Res, 28:203-208, 2005.

18) 厚生労働省健康局総務課生活習慣病対策室: 平成16年国民健康・栄養調査結果の概要. http://www.mhlw.go.jp/houdou/2006/05/h0508-la.html

19) Yoshiike, N., et al.:Epidemiology of obesity and public health strategies forits control in Japan, Asia Pac J Clin Nutr, 11 Suppl 8:S727, 2002.

20) Cole, TJ., et al.:Establishing a standard definition for child overweight andobesity, international survey, BMJ, 320:1240, 2000.

21) Matsushita, Y., et al.:Trends in childhood obesity in Japan over the last 25years from the National Nutrition Survey, Obes Res, 12:205-14, 2004.

22) The International Diabetes Institute, a World Health Organization Collaborating Center for the Epidemiology of Diabetes Mellitus and Health Noncommunicable Diseases:The Asia-Pacific perspective; Redefining obesity and its treatment, Health Communications Australia Pty Limited, 2000.

23) Flegal, K. M., et al.:Prevalence and trends in obesity among US adults, 1999-2000. JAMA, 288:1723,2002

24) Seidell, J. C.:Prevalence and time trends of obesity in Europe; J Endocrinol Invest, 25:813, 2002.

25) Wang, Y., Wang, J. Q.:A comparison of international references forassessment of child and adolescent overweight and obesity in different populations, Eur J Clin Nutr, 56:973, 2002.

26) Chinn, S., Rona, R. J.:Prevalence and trends in overweight and obesity in three cross sectional studies of british children, 1974-94. BMJ, 322:24,2001

27) Kain, J., et al.:Trends in overweight and obesity prevalence in Chileanchildren; comparison of three definitions, Eur J Clin Nutr, 56:200, 2002.

28) Karayiannis, D., et al.:Prevalence of overweight and obesity in Greekschool-aged children and adolescents, Eur J Clin Nutr, 57:1189, 2003.

29) Rolland-Cachera, M. F, et al.:Body mass index in 7-9-y-old French children; frequency of obesity, overweight and thinness, Int J Obes, 26:1610, 2002.

30) メタボリックシンドローム診断基準検討委員会:日本内科学会雑誌, 94:188-203, 2005.

31) Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity:New criteria for 'obesity disease' in Japan, Circulation Journal, 66:987-992, 2002.

32) 厚生労働省健康局総務課生活習慣病対策室:平成15年国民健康・栄養調査結果の概要について, 2005.

33) 厚生労働省健康局総務課生活習慣病対策室:平成17年国民健康・栄養調査結果の概要について, 2007.

34) メタポリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準, 日本内科学会雑誌, 94:794-809, 2005.

35) 日本肥満学会肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン2006, 肥満研究, 12 (臨時増刊), 2006.

36) Neel, J. V.:The"thrifty genotype"in 19. 98, Nutr Rev, 1999 May, 57 (5 Pt 2), S2-9. Review.

37) 占田俊秀:生活習慣病と遺伝子多型;肥満における遺伝子多型の臨床的意義, ホルモンと臨床, 53:903-907, 2005.

38) Mori, H., et al.:The Pro12→Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population; possible involvement in impairment of insulin secretion in individuals with type 2 diabetes, Diabetes 50:891-894, 2001.

39) Hotamisligil, G. S.:The role of TNF alpha and TNF receptors in obesity andinsulin res istance, J Intern Med, hq, 245 (6):621-625, 1999.

40) Arita, Y., et al.:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun, 257 (1):79-83, 1999.

41) Zhang, Y., et al.:Positional cloning of the mouse obese gene and its humanhomologue, Nature, 372:425-432, 1994.

42) Satoh, N., et al.:the arcuate nucleus as aprimary site of satiety effect ofleptin in rats, Neurosci Lett, 224:149-152, 1997.

43) Satoh, N., et al.:Sympathetic activation of leptin via the ventromedicalhypothalamus; leptin-induced increase in catecholamine secretion, Diabetes, 48:1787-1793, 1999.

44) Considine, R. V., et al.:Serum immunoreactive-leptin concentrations innormal-weight and obese humans, N Eugl J Med, 334:292-295, 1996.

45) 佐藤哲子, 小川佳宏:レプチン抵抗性の発現機序とレプチンの臨床応用ホルモンと臨床, 52 (12):71-82, 2004.

46) Schwartz, M. W., et al.:Cerebrospinal fiuid levels:Relationship to plasmalevels and to adiposity in humans, Nat Med, 2:589-593, 1996.

47) El-Hascheimi, K, et al.:Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity,J Clin Invest, 105:1827-1832, 2000.

48) Aizawa-Abe, M., et al.:Pathophysiologic role of leptin in obesity-relatedhypertension, J Clin Invest, 105:1243-1252, 2000.

49) Satoh, N., et al.:Satiety effect and sympathetic activation of leptin aremediated by hypothalamic melanocortin system Neurosci Lett 19 249 107-110 1998.

50) Ebihara, K et al. Involvement of agouti-related protein an endogenousantagonist of hypothalamic melanocortin receptor ln leptin action, Diabetes, 48 2028-2033 1999.

51) Kojima, M., et al. Ghrelin is a growth-hormone-releasing a cylated peptidefrom stomach, Nature, 402 (6762) 656-660 1999.

52) Walston, J., et al. Time of onset of non-insulin-dependent diabetes mellitusand genetic variation in the beta3-adrenergic receptir gene, N Engl J Med, 333 (6):343-347, 1995.

53) Yoshida, T., et al.:Mutation of beta3-adrenergic receptor (Trp64Arg) lowers the response to treatment of obesity, Lancet, 346 (8987):1433-1434, 1995.

54) Enerback, S., et al.:Mice lacking mitochondrial uncopulong protein arecold-sensitive but not obese, Nature, 387 (6628):90-94, 1997.

55) Hayashi, T., et al.:Evidence for 5:AMP-activated protein kinase mediationof the effect of muscle contraction on glucose transport, Diabetes, 47 (8):1369-73, 1998.

56) Yamauchi, T., et al.:A diponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8 (11):1288-1295, 2002.

57) 門脇孝編:糖尿病ナビゲーター<ナビゲーターシリーズ6>, メディカルレビュー社, 2002, p. 152-153.

58) 松澤祐次, 他:新しい肥満の判定と肥満症の診断基準, 肥満研究, 6 (1):1-13, 2000.

59) 日本肥満学会肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン2006, 肥満研究, 12 (臨時増刊), 2006, p.42-48.

60) 吉田俊秀:肥満治療の最前線;遺伝子診断に基づくテーラーメイド型食事指導を含めて, 日本医事新報, 4190:1-5, 2004.

61) 吉田俊秀:日本人が一番やせるダイエット;肥満遺伝子が教えるダイエット成功の法則, マキノ書店, 2006.

62) 吉田俊秀:夜キャベツダイエット, ワニブックス, 2009.

63) 吉田俊秀:肥満専門医が教える成功率93%ダイエット, マキノ書店, 2008.

64) Sturm, R.:Increases in morbid obesity in the USA; 2000-2005, Public Health, 121:492-496, 2007.

65) Buchwald, H., Williams, S. E.:Bariatric surgery worldwide 2003, 0bes Surg, 14:1157-1164, 2004.

66) Lee, W. J., Wang, W.:Bariatric surgery; Asia-Pacific perspective, Obes Surg 15:751-757, 2005.

67) Buchwald, H., et al.:Bariatric surgery; A systematic review and meta-analysis, JAMA, 292:1724-1737, 2004.

68) Chapman, AE, et al.:Laparoscopic adjustable gastric banding in thetreatment of obesity; a systematic literature review, Surgery, 135:326-351, 2004.

69) O'Brien, PE., et al.:Systematic review of medium-term weight loss afterbariatric operations, Obes Surg, 16:1032-1040, 2006.

70) Genco, A., et al.:BioEnterics intragastric balloon; the Italian experiencewith 2, 515 patients, Obes Surg, 15:1161-1164, 2005.

71) 北野正剛, 他:内科治療抵抗性肥満症に対する内視鏡的胃内バルーン留置療法の経験, Gastroenterol Endosc, 47:2197-2201, 2005.

72) 太田正之, 他:本邦における高度肥満患者に対する胃内バルーン留置術と腹腔鏡下冒バンディング術の導入, 日本内視鏡外科学会雑誌, 11:631-638, 2006.

73) 太田正之, 他:高度肥満患者に対する腹腔鏡下調節性胃バンディング術後の体重減少と併存疾患改善効果, 日本消化器外科学会雑誌, 41 (6):599-604, 2008.

75) O'Brien, P. E., et al.:Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program, Ann Intern Med, 144:625-633, 2006.

3 メタボリックシンドロームの概念と病態

P.128 掲載の参考文献

1) Kaplan, N. M.:The deadly quartet; Upper-body obesity, glucoseintolerance, hypertriglyceridemia, and hypertension, Arch Intern Med, 148:1515-1520, 1989.

2) Donahue, R. P., et al.:Central obesity and coronary heart disease in men, Lancet, 1:882-884, 19687.

3) Shear, C. L, et al.:Body fat patterning and blood pressure in children andyoung adults, The Bogalusa Heart Study, Hypertension, 9 (3):236-244, 1987.

4) Freedman, D. S., et al:Relation of body fat distribution to hyperinsulinemiain children and adlescents; the Bogalusa Heart Study, Am J Clin Nutr, 46 (3):403-410, 1987.

5) Reaven, G. M.:Banting lecture 1988; role of insulin resistance in humandisease, Diabetes, 37:1595-1607, 1988.

6) Reaven, G. M.:Syndrome X; 6 years later, J Intern Med, 236:13-22, 1994.

7) De Fronzo, RA, Ferrannini, E.:Insulin resistance; A multifaceted syn-drome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care, 14:173-194, 1991.

8) Matsuzawa, Y., et al.:Pathophysiology and pathogenesis of visceral fatobesity, Obes Res, 3:187-194, 1995.

9) Matsuzawa, Y., et al. Visceral fat accumulation and cardiovascular disease, Obes Res, 3 645S-647S, 1995.

10) Alberti, K. G. M. M Zimmet PZ for the WHO consultation Definitiondiagnosis and classification of diabetes mellitus and its complications Part 1, Diagnosis and classification of diabetes mellitus Provisional report of a WHOconsultation, Dlabetic Med, 15:539-553, 1998.

11) Balkau, B., Charles, M. A. for the European Group for the Study of Insulin Resistance (EGIR) Comment on the provisional report from the WHO consultation, Diabetic Med 16 442-443, 1999.

12) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national holesterol education program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA, 285 2486-2497, 2001

13) Hofman, P. L, et al.:Premature Birth and Later Insulin Resistance, N Engl J Med, 351:2179-2186, 2004.

14) Lawlor, DA, et al.:(Mis) use of factor analysis in the study of insulinresistance, Am J Epidemiol, 159:1013-1018, 2004.

15) Sakkinen, P. A., et al.:Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome, Am J Epidemiol, 152:897-907, 2000. 16) Pladevall, M., et al.:A single factor underlies the metabolic syndrome; A confirmatory factor analysis, Diabetes Care, 29:113-122, 2006.

17) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準, 日本内科学会雑誌, 94:794-809, 20005.

18) The IDF consensus group:The IDF consensus worldwide definition of themetabolic syndrome. 2005. http://www.idf.org/webdata/docs/MetSyndrome-FINAL.pdf

19) Grundy, S. M., et al:Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112:2735-2752, 2005.

20) Lee, J., et al.:Should central obesity be an optimal or essential componentof the metabolic syndrome?; Ischemic heart disease risk in the Singapore cardiovascular cohort study, Diabetes Care, 30:343-347, 2007.

21) 厚生労働省:平成16年国民健康・栄養調査の概要. http://www.mhlw.go.jp/houdou/2006/05/h0508-/a.html

22) Nishimura, R., et al.:Prevalence of metabolic syndrome and optimal waistcircumference cut-off values in Japan, Diabetes Res Clin Pract, 78 (1):77-84, 2007.

23) 大久保賢, 清原裕:一般住民におけるメタボリック・シンドロームの頻度, 臨牀と研究, 81 (11):1736-1740, 2004.

24) Takeuchi, H., et al.:Metabolic syndrome and disease in Japanesemen; applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program-Adult Treatment Panel III to Japanese men; the Tanno and Sobetsu Study, Hypertens Res, 28 (3):203-208, 2005.

25) Arai, H., et al.:Prevalence of metabolic syndrome in the general Japanese population in 2000, J Atheroscler Thromb, 13 (4):202-208, 2006.

26) Ford, E. S., et al.:Prevalence of the metabolic syndrome among US adults; findings from the third National Health and Nutrition Examination Survey, JAMLA, 287 (3):356-369, 2002.

27) Hu, G., et al.:Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women, Arch lntern Med, 164 (10):1066-1076, 2004.

28) Gu, D., et al.:Prevalence of the metabolic syndrome and overweight among adults in China, Lancet, 365 (9468):1398-1405, 2005.

29) Park, H. S., et al.:Prevalence and trends of metabolic syndrome in Korea:Korean National Health and Nutrition Survey 1998-2001, Diabetes Obes Metab, 9 (1):50-58, 2007.

30) Gupta, R., et al.:Prevalence of metabolic syndrome in an Indian urbanpopulation, Int J Cardiol, 97 (2):257-261, 2004.

31) Lakka, H. M., et al.:The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288 (21):2709-2716, 2002.

32) Ninomiya, T., et al.:Impact of metabolic syndrome on the development ofcardiovascular disease in a general Japanese population, the Hisayama study, Stroke, 38 (7):2063-2069, 2007.

33) Iso, H., et al.:Metabolic syndrome and the risk of ischemic heart diseaseand stroke among Japanese men and women, Stroke, 38 (6):1744-1751, 2007.

34) Garrison, RJ., Castelli, W. P.:Weight and thirty-year mortality of men in the Framingham Study, Ann Intern Med, 103:1006-1009, 1985.

35) Willett, W. C., Manson, J. E., Stampfer, MJ., Colditz GA, Rosner B, Speizer FE, Hennekens CH:Weight, weight change, and coronary heart disease inwomen. Risk within the 'normal' weight range, JAMA, 273:461-465, 1995.

36) Lakka, H. M., Laaksonen, DE., Lakka, TA, Niskanen, L. K., Kumpusalo, E., Tuomilehto, J., Salonen, J. T.:The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288:2709-2716, 2002.

37) Ninomiya, T., Kubo, M., Doi, Y., Yonemoto, K., Tanizaki, Y., Rahman, M., Arima, H., Tsuryuya, K., Iida, M., Kiyohara, Y.:Impact of metabolic syndromeon the development of cardiovascular disease in a general Japanese population:the Hisayama study, Stroke, 38:2063-2069, 2007.

38) Yanovski, S. Z., Yanovski, J. A.:Obesity, N Engl J Med, 346:591-602, 2002.

39) Hioki, C., Yoshimoto, K., Toshida, T.:Efficacy of bofu-tsusho-san, anoriental herbal medicine, in obese Japanese women,with impaired glucosetolerance, Clin Exp Pharmacol Physiol, 31:614-619, 2004.

40) 肥満症治療ガイドライン作成委員会:肥満症治療ガイドライン2006, 日本肥満学会, 2006.

41) 本糖尿病学会編:糖尿病治療ガイド2008-2009, 文光堂. 2008.

42) 動脈硬化診療・疫学委員会:動脈硬化性疾患予防ガイドライン, 2007年版, 日本動脈硬化学会, 2007.

43) Hu, F. B., Stampfer, M. J., Manson, J. E., Rimm, E., Colditz, GA, Rosner, B. A., Hennekens, C. H., Willett, W. C.:Dietary fat intake and the risk of coronary heart disease in women, N Engl J Med, 337:1491-1499, 1997.

44) McMillan-Price, J., Petocz P, Atkinson, F., O'neill, K., Samman, S., Steinbeck, K., Caterson, I., Brand-Miller, J.:Comparison of 4 diets of varyingglycemic load on weight loss and cardiovascular risk reduction in overweightand obese young adults:a randomized controlled trial, Arch Intern Med, 166:1466-1475, 2006.

45) Sacks, FM., Svetkey, L. P., Vollmer, W. M., Appel, LJ., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R. 3rd, Simons-Morton, D. G., Karanja, N., Lin, P. H.; DASH-Sodium Collaborative Research Group:Effectson blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet, N Engl J Med, 344:3-10, 2001.

46) Gan, S. K., Kriketos, A. D., Ellis, B. A, Thompson, C. H., Kraegen, E. W., Chisholm, D. J.:Changes in aerobic capacity and visceral fat but not myocytelipid levels predict increased insulin action after exercise in overweight andobese men, Diabetes Care, 26:1706-1713, 2003.

47) Torjesen, P. A, Birkeland, KI., Anderssen, SA., Hjermann, I., Holme, I., Urdal, P.:Lifestyle changes may reverse development of the insulin resistance syndrome, The Oslo Diet and Exercise Study, a randomized trial, Diabetes Care, 20:26-31, 1997.

48) 厚生労働省:健康づくりのための運動基準2006;身体活動・運動・体力, 2006.

49) 厚生労働省:健康づくりのための運動指針2006;生活習慣病予防のために(エクササイズガイド2006), 2006.

50) Iso, H., Sato, S., Kitamura, A., Imano, H., Kiyama, M., Yamagishi, K., Cui, R., Tanigawa, T., Shimamoto, T.:Metabolic syndrome and the risk of ischemicheart disease and stroke among Japanese men and women, Stroke, 38:1744-1751, 200Z

51) Sattar, N., et al.:Metabolic syndrome with and without C-reactive protein asapredictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108:414-419, 2003.

52) Knowler, W.C., et al.:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346:393-403, 2002.

53) Tuomilehto, J., et al:Prevention of type 2 diabetes mellitus by changes inlifestyle among subjects with impaired glucose tolerance, N Engl J Med, 344:1343-1350, 2001.

54) DREAM Trial Investigators:Effect of ramipril on the incidence of diabetes, N Engl J Med, 355:1551-1562, 2006.

55) Kahn, S. E., et al.:Glycemic durability of rosiglitazone, metformin, orglyburide monotherapy, N Engl J Med, 355:2427-2443, 2006.

56) Dormandy, J. A., et al.:Secondary prevention of macrovascular events inpatients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial in macrovascular Events):arandomised controlled trial, Lancet, 366:1279-1289, 2005.

57) Mazzone, T., et al.:Effect of pioglitazone compared with glimepiride oncarotid intilna-media thickness in type 2 diabetes, A randomized trial, JAMA, 296:2572-2581, 2006.

58) Nissen, S. E., et al.:Comparison of pioglitazone vs glimepiride onprogression of coronary atherosclerosis in patients with type 2 diabetes:the PERISCOPE randomized controlled trial, JAMA, 299:1561-1573, 2008.

59) Genuth, S., et al.:Follow-up report on the diagnosis of diabetes mellitus, Diabetes Care, 26:3160-3167, 2003.

60) Alberti, KG., et al.:The metabolic syndrome-a new worldwide definition, Lancet, 366:1059-1062, 2005.

61) Grundy, S. M., et al.:Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112:2735-2752, 2005.

62) Castelli, W. P., et al.:Incidence of coronaly heart disease and lipoproteincholesterol levels, The Framingham Study, JAMA, 256:2835-2838, 1986.

63) Okamura, T., et al:The relationship between serum total cholesterol andall-cause or causespeci:fic mortality in a 17.3-year study of a Japanese cohort, Artherosclerosis, 190:216-223, 2007.

64) Baigent, C., et al.:Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomisedtrials of statins, Lancet, 366:1267-1278, 2005.

65) Iso, H., et al.:Serum triglycerides and risk of coronary heart disease among Japanese men and women, Am J Epidemiol, 153:490-499, 2001.

66) Kitamura, A., et al.:High-density lipoprotein cholesterol and prematurecoronary heart disease in urban Japanese men, Circulation, 89:2533-2539, 1994.

67) Kannel, W. B., et al.:Fifty years of Framingham Study contributions tounderstanding hypertension, J Hum Hypertens, 14:83-90, 2000.

68) Lida, M., et al.:Impact of elevated blood pressure on mortality from allcauses, cardiovascular diseases, heart disease and stroke among Japanese:14year follow-up of randomly selected population from Japanese-Nippondata 80, J Hum Hypertens, 17:851-857, 2003.

69) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2004, 日本高血圧学会, 2004.

70) Schillaci, G., et al.:Prognostic value of the metabolic syndrome in essentialhypertension, J Arn Coll Cardiol, 43:1817-1822, 2004.

71) Mancia, G., et al.:2007 Guidelines fbr the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertensionof the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), JHypertens, 25:1105-1187, 2007.

72) Julius, S., et al.:Feasibility of treating prehypertension with an angiotensin-receptor blocker, N Engl J Med, 354:1685-1697, 2006.

73) Niskanen, L., Turpeinen A, Penttila I, Uusitupa MI:Hyperglycemia andcompositional lipoprotein abnormalities as predictors of cardiovascularmortality in type 2 diabetes:a 15-year follow-up from the time of diagnosis, Diabetes Care, 21:1861-1869, 1998.

4 メタボリックシンドロームの予防・改善のための保健指導

P.153 掲載の参考文献

1) 安藤潔編著:メディカル・コーチングQ & A:医療・看護の現場からの質問40, 真興交易医書出版部, 2006.

P.186 掲載の参考文献

1) 厚生労働省厚牛科学審議会地域保健健康増進栄養部会:「健康日本21」中間評価報告書, 2007.

2) 厚生労働省:平成16年国民健康・栄養調査.

3) 津下一代:最新の科学的知見に基づいた保健事業に係る調査研究(厚生労働科学特別研究. 主任研究者福井次矢), 2004,

4) US Preventive Services Task Force:Physical activity counseling. http://www.ahcpr.gov/clinic/uspstf/uspsphys.htm

5) 厚生労働省健康局:標準的な健診・保健指導プログラム(確定版), 2007. http://www.niph.go.p/soshiki/jinzai/koroshoshiryo/kenshin/index.htm

6) メタボリックシンドローム診断基準委員会:メタボリックシンドロームの定義と診断基準, 日本内科学会雑誌, 94:188-203, 2005.

7) 津下一代:相手の心に届く保健指導のコツ, 東京法規出版, 2007.

8) 厚生労働省保険局:特定健康診査・特定保健指導の円滑な実施に向けた手引き, 2007.

9) 日本遠隔医療学会編:テレメンタリング;双方向ツールによるヘルスケア・コミュニケーション, 中山書店, 2007.

10) NPO法人日本健康運動指導士会編:特定保健指導における運動指導マニュアル, サンライフ企画, 2007.

11) 津下一代:これから必要とされる保健指導のコンテンツとは?, 保健師ジャーナル, 62 (10):796-801, 2006.

12) 坂根直樹:楽しく患者をやる気にさせる糖尿病教育;体験型糖尿病教室のススメ, 日本医学出版, 2003, p. 13.

13) 日本糖尿病学会編:糖尿病治療ガイド2008-2009, 文光堂, 2008, p. 34.

14) 菅原裕子:コーチングの技術;上司と部下の人間学<講談社現代新書>, 講談社, 2003.

15) 坂田利家編:肥満症治療マニュアル, 医歯薬出版, 1996, p. 123.

16) 東めぐみ:糖尿病看護における熟練看護師のケアの分析, 日本糖尿病教育・看護学会誌, (2) 100-113, 2005.

17) 安酸史子, 他:患者教育に必要な看護職者のProfessional Learning Climate, 看護研究, 36 (3) 51-62, 2003.

18) 厚生労働省生活習慣病対策室新たな健診・保健指導と生活習慣病対策.

19) 吉田亨, 他:患者教育の新しい考え方, プラクティス, 9 (1):58-59, 1992.

20) 吉田亨:健康教育と栄養教育 (2) ;指導型の教育と学習援助型の教育, 臨床栄養, 85 (5) 621-627, 1994.

21) 吉田亨:健康教育と栄養教育 (1) 健康教育の歴史と栄養教育, 臨床栄養, 85 (3), 317-323, 1994.

22) ジェイムス・プロチャスカ, 他著, 中村正和監訳, 赤松利恵, 他訳:チェンジング・フォー・グッド;ステージ変容理論で上手に行動を変える, 法研, 2005.

23) Harwath, C. C.:Applying the Transtheoretical Model to eating behavior change:challenges and opportunities. Nutr Res Rev, 12:281-317, 1999.

24) 赤松利恵, 武見ゆかりトランスセオレティカルモデルの栄養教育への適用に関する研究の動向, 日本健康教育学会誌, 15 (1) 3-18, 2007.

25) Kristal, A. R., Glanz, K, Curry, SJ., Patterson, R. E.:How can stage of change be best in dietary interventions?, J Am. Diet Assoc, 99:679-684, 1999.

26) 足達淑子:行動変容をサポートする保健指導バイタルポイント;情報提供・動機づけ支援・積極的支援, 医歯薬出版, 2007.

27) 足達淑子編:ライフスタイル療法1;生活習慣改善のための行動療法, 第3 版, 医歯薬出版, 2006.

28) 足達淑子, 他編:栄養教育論<健康・栄養科学シリーズ>, 南江堂, 2005.

29) 吉田亨:健康教育と栄養教育 (3) ;健康教育の方法, 臨床栄養, 85 (6):741-747, 1994.

30) 足達淑子:特定保健指導の視点とポイント, 臨床栄養, 111 (3), 2007.

31) Contento, I. R.:Nutrition Education; linking research, theory, and practice, Jones & Bartlett Publishers, 2007.

32) ジェフリー・ローズ著, 曽田研二, 田中平三監訳, 水嶋春朔, 他訳:予防医学のストラテジー;生活習慣病対策と健康増進, 医学書院, 1998.

33) 杉山みち了:栄養教育のマネジメント, 臨床栄養, 101 (7):794-802, 2002. 34) 足立己幸, 秋山房雄:食生活論, 医歯薬出版, 1987.

35) 厚生労働省:健康づくりのための運動基準2006;身体活動・運動・体力, 2006.

36) 厚生労働省:健康づくりのための運動指針2006;エクササイズガイド 2006, 2006.

47) 竹中晃一二, 冨樫陽子:運動指導者のための行動変容入門;ライフスタイルプランナーへの道, 早稲田大学応用健康科学研究室, 2005.

5 肥満・メタボリックシンドロームに関連する特殊な病態

P.216 掲載の参考文献

1) 日本肝臓学会編:NASH・NAFLDの診療ガイド, 文光堂, 2006.

2) Ludwig, J., et al.:Nonalcoholic steatohepatitis; Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 55:434-438, 1980.

3) Schaffner, F, Thaler, H.:Nonalcoholic fattly liver disease, Prog Liver Dis, 8:283-298, 1986.

4) Pessayre, D., et al.:NASH; a mitochondrial disease, (Review) J Hepatol, 42:928-940, 2005.

5) Weltman, M. D., et al.:Hepatic cytochrome P450 2E1 is increased inpatients with nonalcoholic steatohepatitis, Hepatology, 27:128-133, 1998.

6) Sumida, Y., et al.:Serum thioredoxin levels as a predictor of steatohepatitisin patients with nonalcoholic fatty liver disease, J Hepatol, 38:32-38, 2003.

7) Weisberg, S. P et al. Obesity is associated with macrophage accumulationln adipose tissue, J CLin. Invest, 112 1796-1808 2003

8) Yamauchi, T., et al. A diponectin stimulates glucose utilization and fatty-acid oxldation by activating AMP-activated protein kinase, Nat Med 1288-1295, 2002.

9) Yamauchi, T., et al. The fat-derived hormone adiponectin reverses insulinresistance associated with both lipoatrophy and obesity, Nat Med 941-946, 2001.

10) Yamauchi, T., et al. Globular diponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis, J Biol Chem, 2782461-2468 2003

11) Kamada, Y., et al. Enhanced carbon tetrachbrideinduced liver fibrosis in mice lacking adiponectin. Gastroenterology, 125:1796-1807, 2003

12) Ikejima, K., et al. Leptin receptor-mediated signaling regulates hepaticfibrogenesis and remodeling of extracellular matrix in the rat Gastroenterology, 122 1399-1410 2002

13) Brunt, E. M., et al. Nonalcoholic steatohepatitis:A proposal for grading and staging the histological lesions, Am J Gastroenterol, 94 2467-2474, 1994.

14) 橋本悦子:非アルコール性脂肪性肝炎4; 臨床経過と予後, 肝臓, 45:71-76, 2004.

15) 橋本悦子:NASHに基づく肝硬変・肝細胞癌, 肝胆膵, 51; 883-891, 2005.

16) Farrell, G. C., et al.:Nonalcoholic fatty liver disease; from steatosis tocirrhosis, Hepatology, 43, S99-S112, 2006.

17) Hashimoto, E., et al.:The characteristics and natural history of Japanesepatients with nonalcoholic fatty liver disease, Hepatol Res, 33:72-76, 2005.

18) Snyal, A. J., et al.:Similarities and differences in outcomes of cirrhosis dueto nonalcoholic steatohepatitis and hepatitis C, Hepatology, 43:682-689, 2006.

19) Belfort, R., et al.:A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis, 355:2297-2307, 2006.

20) Marchesini, G., et al.:Metformin in non-alcoholic steatohepatitis, 359:355-356, 2001.

21) Basaranoglu, M., et al.:A controlled trial of gemfibrozil in the treatment ofpatients with non-alcoholic steatohepatitis, J Hepatol, 31:384, 1999.

22) Yokohama, S., et al.:Therapeutic efficacy of an angiotensin H receptorantagonist in patients with nonalcoholic steatohepatitis, Hepatology 40:1222-1225, 2004.

23) Sasanabe, R, et al.:Metabolic syndrome in Japanese patients withobstructive sleep apnea syndrome, Hyperten Res, 29:315-322, 2006.

24) Marin, J. M., et al.:Long-term cardiovascular outcomes in men withobstructive sleep apnea-hypopnea with or without treatment with continuouspositive airway pressure, an observational study, Lancet, 365:1046-1053, 2005.

25) Yaggi, H. K., et al.:Obstructive sleep apnea as a risk factor for stroke and death, N Engl J Med, 353:2034-2041, 2005.

26) Kitahara, Y., et al.:Effect of CPAP on brachial-ankle pulse wave velocity in patients with OSAHS, An open-labelled study, Respiratory Medicine, 100:2160-2169, 2006.

27) American Academy of Sleep Medicine:The International Classification of Sleep Disorders:Diagnostic and Coding Manual, 2nd ed, 2005

28) 杉山重幸, 他:睡眠時無呼吸症候群患者におけるCPAP療法コンプライアンスの改善について, 日本睡眠学会第31回定期学術集会プログラム・抄録集, 171:57, 2006.

書評

書評を投稿する

最近チェックした商品履歴

Loading...